Oakbrook Investments Has Decreased Cigna (CI) Position; Volitionrx Limited (NYSEAMERICAN:VNRX) Shorts Increased By 10.62%

June 24, 2018 - By Adrian Erickson

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Oakbrook Investments Llc decreased Cigna Corporation (CI) stake by 14.16% reported in 2018Q1 SEC filing. Oakbrook Investments Llc sold 2,230 shares as Cigna Corporation (CI)’s stock declined 10.20%. The Oakbrook Investments Llc holds 13,523 shares with $2.27 million value, down from 15,753 last quarter. Cigna Corporation now has $42.35B valuation. The stock decreased 0.53% or $0.92 during the last trading session, reaching $174.08. About 2.53 million shares traded or 26.20% up from the average. Cigna Corporation (NYSE:CI) has risen 8.82% since June 24, 2017 and is uptrending. It has underperformed by 3.75% the S&P500. Some Historical CI News: 07/03/2018 – CIGNA IS NEARING A DEAL TO BUY EXPRESS SCRIPTS – CNBC CITING DOW JONES; 09/03/2018 – Rep. Larson: Larson Statement on Announcement that Cigna is Acquiring Express Scripts; 08/03/2018 – The $54 billion Cigna-Express Scripts deal is the latest move in an industry aiming to tackle soaring healthcare costs; 08/03/2018 – Cigna Sees Debt-To-Capitalization Ratio About 49% After Acquisition; 08/03/2018 – Another health company, insurer Cigna, announces plans to acquire pharmacy benefit manager Express Scripts; 16/05/2018 – CIGNA SAYS IT CONSIDERED BUYING A LARGE PUBLIC HEALTH COMPANY; 28/03/2018 – FDA’s Gottlieb eyes PBM consolidation impact on generic entry-CNBC; 09/05/2018 – Cigna Named to Corporate Responsibility Magazine’s 100 Best Corporate Citizens List for Fourth Consecutive Year; 13/03/2018 – Bank fee potential slashed as Trump ends Broadcom’s Qualcomm takeover; 08/03/2018 – EXPRESS SCRIPTS HOLDING CO – UPON CLOSING, COMBINED COMPANY WILL BE LED BY DAVID M. CORDANI AS PRESIDENT AND CEO

Volitionrx Limited (NYSEAMERICAN:VNRX) had an increase of 10.62% in short interest. VNRX’s SI was 408,300 shares in June as released by FINRA. Its up 10.62% from 369,100 shares previously. With 160,800 avg volume, 3 days are for Volitionrx Limited (NYSEAMERICAN:VNRX)’s short sellers to cover VNRX’s short positions. The SI to Volitionrx Limited’s float is 2.23%. The stock decreased 0.90% or $0.02 during the last trading session, reaching $2.2. About 20,168 shares traded. VolitionRx Limited (NYSEAMERICAN:VNRX) has declined 33.81% since June 24, 2017 and is downtrending. It has underperformed by 46.38% the S&P500. Some Historical VNRX News: 14/05/2018 – VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018; 13/03/2018 – VolitionRx Announces Closing of $8.4 M Public Offering of Common Stk; 28/05/2018 – VolitionRX Conference Scheduled By Edison for Jun. 4-6; 09/03/2018 – VolitionRx Announces Pricing of $8.4M Public Offering of Common Stk; 09/05/2018 – VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits; 07/03/2018 – VolitionRx Appoints Harvard Professor Lee-Jen Wei to Scientific Advisory Board; 08/03/2018 – VolitionRx Announces Proposed Underwritten Public Offering of Common Stk; 21/05/2018 – VolitionRX at Non-Deal Roadshow Hosted By Edison Today; 07/03/2018 VOLITIONRX APPOINTS HARVARD PROFESSOR, DR. LEE-JEN WEI TO ITS SCIENTIFIC ADVISORY BOARD; 14/05/2018 – VolitionRX Non-Deal Roadshow Scheduled By Edison for May. 21-22

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $66.07 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

Investors sentiment increased to 3.25 in Q1 2018. Its up 2.05, from 1.2 in 2017Q4. It is positive, as 1 investors sold VolitionRx Limited shares while 3 reduced holdings. 8 funds opened positions while 5 raised stakes. 9.29 million shares or 105.34% more from 4.52 million shares in 2017Q4 were reported. Knoll Mgmt L P has 0.87% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Bessemer Gp reported 10,000 shares. Garrison Bradford And Associate reported 0.03% in VolitionRx Limited (NYSEAMERICAN:VNRX). Tower Rech Ltd Liability (Trc) has 596 shares. Sabby Mngmt Limited Company accumulated 13,167 shares. 11,015 were accumulated by Bluecrest Cap Mngmt Limited. Bridgeway Cap reported 0.01% in VolitionRx Limited (NYSEAMERICAN:VNRX). Barclays Public Ltd Com reported 0% stake. Credit Suisse Ag invested in 0% or 65,000 shares. Creative Planning has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Skylands Capital has 121,100 shares for 0.04% of their portfolio. Blackrock reported 4,982 shares. Lagoda Inv Lp reported 3.19 million shares or 2.88% of all its holdings. Stratos Wealth Ptnrs Ltd holds 0% or 2,000 shares. Morgan Stanley has invested 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX).

Since January 10, 2018, it had 0 insider purchases, and 11 insider sales for $17.48 million activity. Shares for $1.12M were sold by Jones Nicole S. 2,759 Cigna Corporation (NYSE:CI) shares with value of $529,287 were sold by Hocevar Christopher J. Another trade for 229 shares valued at $37,890 was sold by ZOLLARS WILLIAM D. Another trade for 1,000 shares valued at $176,187 was sold by Agoglia Hoeltzel Mary T. MURABITO JOHN M also sold $5.77 million worth of Cigna Corporation (NYSE:CI) shares. Another trade for 5,971 shares valued at $1.29M was sold by ZARCONE DONNA F. HENNEY JANE E MD also sold $85,184 worth of Cigna Corporation (NYSE:CI) on Friday, January 12.

Oakbrook Investments Llc increased Costco Wholesale Corporation (NASDAQ:COST) stake by 38,575 shares to 43,900 valued at $8.27M in 2018Q1. It also upped Microsoft Corporation (NASDAQ:MSFT) stake by 10,355 shares and now owns 373,517 shares. Baxter International Inc. (NYSE:BAX) was raised too.

Among 22 analysts covering CIGNA (NYSE:CI), 19 have Buy rating, 0 Sell and 3 Hold. Therefore 86% are positive. CIGNA has $255 highest and $134 lowest target. $210’s average target is 20.63% above currents $174.08 stock price. CIGNA had 67 analyst reports since July 27, 2015 according to SRatingsIntel. Piper Jaffray initiated the shares of CI in report on Wednesday, January 4 with “Overweight” rating. Evercore initiated Cigna Corporation (NYSE:CI) rating on Friday, September 23. Evercore has “Hold” rating and $134 target. The stock of Cigna Corporation (NYSE:CI) has “Outperform” rating given on Thursday, June 22 by RBC Capital Markets. The company was maintained on Monday, March 26 by Jefferies. The firm earned “Buy” rating on Friday, August 4 by Oppenheimer. Deutsche Bank maintained the shares of CI in report on Thursday, July 13 with “Buy” rating. The firm has “Buy” rating given on Friday, August 4 by Jefferies. The firm has “Buy” rating by Deutsche Bank given on Monday, August 7. RBC Capital Markets maintained Cigna Corporation (NYSE:CI) rating on Tuesday, August 18. RBC Capital Markets has “Sector Perform” rating and $182 target. The firm earned “Overweight” rating on Wednesday, June 7 by Morgan Stanley.

More news for Cigna Corporation (NYSE:CI) were recently published by: Benzinga.com, which released: “Cigna Set To Disrupt Commercial Risk Market, Goldman Sachs Says In Upgrade” on June 06, 2018. Fool.com‘s article titled: “3 Big Implications of the AT&T-Time Warner Decision” and published on June 13, 2018 is yet another important article.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts